3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Glioma
3
Wilms Tumor
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Gliosarcoma
1
Glioblastoma
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Interventions
Flow Cytometry
5
Therapeutics
4
Psychiatric Rehabilitation
4
Cyclophosphamide
4
Radiotherapy
3
Polymerase Chain Reaction
3
Melphalan
3
Amplified Fragment Length Polymorphism Analysis
3
sargramostim
2
liposomal amphotericin B
2
Thiotepa
2
Peripheral Blood Stem Cell Transplantation
2
Ondansetron
2
Methylprednisolone
2
Itraconazole
2
Ipilimumab
2
Immunologic Techniques
2
Filgrastim
2
Fentanyl
2
Early Intervention, Educational
2
Dexamethasone
2
Caspofungin
2
Calcium Dobesilate
2
CTLA-4 Antigen
2
Aprepitant
2
Alemtuzumab
2
thymoglobulin
1
tazemetostat
1
imetelstat
1
dostarlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hodgkin Disease
×
CLR1404
×
CNS
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled